Vantage logo

Novo makes a gene editing move

Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.

Vantage logo

Here come the PD-1 agonists

Lilly shows that peresolimab is a goer, and others are not far behind; but what about the cancer risk?